Elicio Therapeutics, Inc.
General ticker "ELTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $113.5M (TTM average)
Elicio Therapeutics, Inc. follows the US Stock Market performance with the rate: 40.0%.
Estimated limits based on current volatility of 4.1%: low 7.85$, high 8.53$
Factors to consider:
- Total employees count: 32 as of 2024
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.01$, 8.97$]
- 2025-12-31 to 2026-12-31 estimated range: [2.30$, 7.09$]
Short-term ELTX quotes
Long-term ELTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $23.73MM | $35.74MM | $44.99MM |
| Operating Income | $-23.73MM | $-35.74MM | $-44.99MM |
| Non-Operating Income | $-4.47MM | $0.55MM | $-6.91MM |
| Interest Expense | $3.60MM | $1.06MM | $0.46MM |
| R&D Expense | $17.05MM | $22.68MM | $33.66MM |
| Income(Loss) | $-28.21MM | $-35.20MM | $-51.90MM |
| Profit(Loss)* | $-28.21MM | $-35.20MM | $-51.90MM |
| Stockholders Equity | $8.91MM | $11.37MM | $-11.31MM |
| Assets | $22.66MM | $27.15MM | $28.18MM |
| Operating Cash Flow | $-22.18MM | $-32.69MM | $-37.07MM |
| Capital expenditure | $0.65MM | $0.07MM | $0.09MM |
| Investing Cash Flow | $-0.65MM | $-0.03MM | $-0.08MM |
| Financing Cash Flow | $21.20MM | $38.61MM | $42.32MM |
| Earnings Per Share** | $-9.10 | $-6.96 | $-4.25 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.